The Leading Bank for Business*

Life Sciences

At Comerica, we’ve become a leader in life sciences businesses by becoming experts in biotech, pharma, health care services and more.

From financing equipment and accessing capital, to managing operating expenses, customer acquisition and liquidity, our life sciences advisors bring decades of experience.

Advisors, not just bankers

Our clients seek business financial solutions for efficiencies, profitability and growth, not just rates and terms.

Dedicated business financial advisors are here to help plan, guide and consult life sciences businesses and venture capitalists by providing term loans and revolving credit facilities for growth capital, working capital, refinancing, restructuring and recapitalization, as well as mergers and acquisitions.

Life sciences specialists

With such a long road from research to product launch, the life sciences industry demands a financial partner with a complete understanding of the development cycle.

We specialize in the life sciences industry by bringing a wealth of insight, experience and networking to help U.S.-based life sciences and health care companies in all stages of development, including:

Biotech
Pharma
Medical device
Diagnostic
Health care services
Health care IT

Business financial solutions

We begin by understanding your business from the ground up before we recommend how to help you grow.

Our needs-based consultative process is built around you, with customized banking solutions that include:

SaaS subscription lines of credit¹
Growth and working capital strategies
Equipment lending¹
International trade finance
Foreign currency hedging
EXIM banking services

Private equity funding

We provide our clients with customized solutions ranging from $500,000 to $100 million.

LEARN MORE

Economic Commentary

Maximize your opportunities.

Get your complimentary consultation from the Leading Bank for Business.

Contact Comerica at 888-812-3118.

*Comerica ranks first nationally among U.S. financial holding companies with greater than $60B in assets, based on commercial and industrial loans outstanding as a percentage of assets, as of December 31, 2022. Data provided by S&P Global Market Intelligence.

¹Loans subject to credit approval.

Quick Links